What does this research mean for the field?

GLP-1 receptor agonists (GLP-1RAs) are primarily initiated in type 2 diabetes patients after the use of three or more glucose-lowering agents, in line with UK clinical guidelines. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

To analyze treatment patterns before the initiation of GLP-1 receptor agonists in patients with type 2 diabetes in the UK.

March 1, 2026

Real-world treatment trajectories preceding GLP-1 receptor agonist initiation in type 2 diabetes: A descriptive UK population-based cohort study on adherence to national clinical guidelines.

Key Points

To analyze treatment patterns before the initiation of GLP-1 receptor agonists in patients with type 2 diabetes in the UK.
Descriptive cohort study design
Population-based data analysis in the UK
Assessment of treatment trajectories prior to GLP-1RA initiation
Most patients initiated GLP-1RAs after using three or more glucose-lowering agents
Post-2018, many received SGLT-2 inhibitors alongside GLP-1RAs
CVD history did not affect prescribing patterns

Abstract

GLP-1RAs were predominantly initiated following ≥3 glucose-lowering agents, consistent with contemporary UK guidance (NG28). Post-2018, most GLP-1RA initiators received SGLT-2is concomitantly. However, CVD history did not influence prescribing patterns, underscoring missed opportunities to optimise the prevention of cardiovascular events and slow the progression of CVD.

Real-world treatment trajectories preceding GLP-1 receptor agonist initiation in type 2 diabetes: A descriptive UK population-based cohort study on adherence to national clinical guidelines.

Key Points

Abstract

Cite This Study